Home > Boards > US Listed > Medical - Drugs > Merck & Co. Inc. (MRK)

FDA approves MRK’s Recarbrio (a combination of three

Public Reply | Private Reply | Keep | Last ReadPost New MsgReplies (1) | Next 10 | Previous | Next
DewDiligence Member Profile
Member Level 
Followed By 739
Posts 113,241
Boards Moderated 15
Alias Born 09/05/02
160x600 placeholder
Gilead Shows the Dangers of Covid-19 Drug Mania -- Heard on the Street Dow Jones News - 8/3/2020 7:29:00 AM
Merck Animal Health Completes Acquisition of Worldwide Rights to VECOXAN® Brand of Parasiticides for Ruminant Portfolio Business Wire - 8/3/2020 6:30:00 AM
Merck Expects Nearly $2 Billion Covid-19 Revenue Impact in 2020 Dow Jones News - 7/31/2020 7:56:00 AM
Merck 2Q Profit Rises Despite Lower Revenue Dow Jones News - 7/31/2020 7:50:00 AM
 Merck Announces Second-Quarter 2020 Financial Results Business Wire - 7/31/2020 6:45:00 AM
Merck Announces Two US Regulatory Milestones for KEYTRUDA® (pembrolizumab) in Triple-Negative Breast Cancer (TNBC) Business Wire - 7/30/2020 6:45:00 AM
Merck Gets FDA Breakthrough Therapy Designation for MK-6482 Dow Jones News - 7/29/2020 9:35:00 AM
FDA Grants Breakthrough Therapy Designation to Merck’s Novel HIF-2α Inhibitor MK-6482 for Treatment of Certain Patients Wi... Business Wire - 7/29/2020 6:45:00 AM
Merck Announces Fourth-Quarter 2020 Dividend Business Wire - 7/28/2020 1:30:00 PM
Pharma Companies Split on Coronavirus Vaccine Pricing Plans Dow Jones News - 7/21/2020 6:09:00 PM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 7/20/2020 4:53:42 PM
Bayer: US FDA Grants Priority Review to New Drug Application for Vericiguat Dow Jones News - 7/16/2020 7:42:00 AM
Merck Gets FDA Priority Review of Vericiguat New Drug Application Dow Jones News - 7/16/2020 7:41:00 AM
FDA Grants Priority Review to Merck’s New Drug Application for Vericiguat Business Wire - 7/16/2020 6:45:00 AM
Merck Animal Health Gets FDA Approval of Bravecto Monthly Chews Dow Jones News - 7/9/2020 5:40:00 PM
Merck Animal Health Receives U.S. FDA Approval of BRAVECTO® (fluralaner) Monthly Chews Business Wire - 7/9/2020 4:30:00 PM
Merck Gets FDA Priority Review of Keytruda in Classical Hodgkin Lymphoma Dow Jones News - 7/9/2020 7:29:00 AM
FDA Grants Priority Review to Merck’s Supplemental Biologics License Application for KEYTRUDA® (pembrolizumab) for Second-... Business Wire - 7/9/2020 6:45:00 AM
Merck Announces Appointment of Organon & Co. General Counsel Business Wire - 7/8/2020 4:30:00 PM
AstraZeneca, Merck Get Europe OK for Lynparza in Pancreatic Cancer Dow Jones News - 7/8/2020 7:59:00 AM
LYNPARZA® (olaparib) Approved in the EU for Germline BRCA-mutated Metastatic Pancreatic Cancer Business Wire - 7/8/2020 6:55:00 AM
Merck & Eisai Receive Complete Response Letter for KEYTRUDA® (pembrolizumab) plus LENVIMA® (lenvatinib) Combination as Firs... Business Wire - 7/8/2020 6:45:00 AM
Merck Announces New Analyses Showing Additional Safety & Efficacy Data for Investigational Islatravir in Combination with Dor... Business Wire - 7/6/2020 6:45:00 AM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 7/2/2020 3:45:50 PM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 7/2/2020 2:46:30 PM
DewDiligence Member Level  Thursday, 06/04/20 11:15:26 PM
Re: None
Post # of 549 
FDA approves MRK’s Recarbrio (a combination of three agents) for hospital-acquired bacterial pneumonia and ventilator-associated bacterial pneumonia:

https://www.prnewswire.com/news-releases/fda-approves-antibiotic-to-treat-hospital-acquired-bacterial-pneumonia-and-ventilator-associated-bacterial-pneumonia-301071053.html

Recarbrio was previously FDA-approved for patients with complicated urinary tract infections and complicated intra-abdominal infections.

“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”
Public Reply | Private Reply | Keep | Last ReadPost New MsgReplies (1) | Next 10 | Previous | Next
Follow Board Follow Board Keyboard Shortcuts Report TOS Violation
X
Current Price
Change
Volume
Detailed Quote - Discussion Board
Intraday Chart
+/- to Watchlist